Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Aug 28;7(9):708.
doi: 10.3390/jof7090708.

Mucormycosis in CAPA, a Possible Fungal Super-Infection

Paola Saltini  1   2   3 , Emanuele Palomba  1   2   3 , Valeria Castelli  1   2   3 , Marco Fava  1   2   3 , Laura Alagna  1 , Simona Biscarini  1 , Marco Mantero  2   4 , Francesco Blasi  2   4 , Anna Grancini  5 , Alessandra Bandera  1   2   3 , Andrea Gori  1   2   3 , Antonio Muscatello  1 , Andrea Lombardi  1   2
Affiliations
Case Reports

Mucormycosis in CAPA, a Possible Fungal Super-Infection

Paola Saltini et al. J Fungi (Basel). .

Abstract

The occurrence of pulmonary fungal superinfection due to Aspergillus spp. in patients with COVID-19 is a well-described complication associated with significant morbidity and mortality. This can be related to a directed effect of the virus and to the immunosuppressive role of the therapies administered for the disease. Here, we describe the first case of pulmonary infection due to Mucorales occurring in a patient with a concomitant diagnosis of COVID-19-associated pulmonary aspergillosis.

Keywords: CAPA; COVID-19; mucormycosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Timeline of the case, highlighting the therapies administered, the respiratory support provided and the evolution of the pulmonary lesion (A chest CT scan at day 38 since diagnosis, B chest CT scan at day 51 since diagnosis, C chest CT scan at day 58 since diagnosis).
See this image and copyright information in PMC

References

    1. WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19—11 March 2020. [(accessed on 17 March 2020)]. Available online: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-re....
    1. Williamson E.J., Walker A.J., Bhaskaran K., Bacon S., Bates C., Morton C.E., Curtis H.J., Mehrkar A., Evans D., Inglesby P., et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–436. doi: 10.1038/s41586-020-2521-4. - DOI - PMC - PubMed
    1. Zhang Y., Geng X., Tan Y., Li Q., Xu C., Xu J., Hao L., Zeng Z., Luo X., Liu F., et al. New understanding of the damage of SARS-CoV-2 infection outside the respiratory system. Biomed. Pharm. 2020;127:110195. doi: 10.1016/j.biopha.2020.110195. - DOI - PMC - PubMed
    1. Qin C., Zhou L., Hu Z., Zhang S., Yang S., Tao Y., Xie C., Ma K., Shang K., Wang W., et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin. Infect. Dis. 2020;71:762–768. doi: 10.1093/cid/ciaa248. - DOI - PMC - PubMed
    1. Sterne J., Murthy S., Diaz J.V., Slutsky A.S., Villar J., Angus D.C., Annane D., Azevedo L.C.P., Berwanger O., Cavalcanti A.B., et al. Association between Administration of Systemic Corticosteroids and Mortality among Critically Ill Patients with COVID-19, A Meta-analysis. JAMA—J. Am. Med. Assoc. 2020;324:1330–1341. doi: 10.1001/jama.2020.17023. - DOI - PMC - PubMed

Publication types

LinkOut - more resources